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The idiopathic hypereosinophilic syndrome (IHES) is characterized by sustained
peripheral blood eosinophilia associated with organ involvement in the absence of
adefined etiology (1). The isolation ofeosinophilsfrom patients with IHEShasresulted
in the identification of a population ofeosinophils ofalower sedimentation density
(hypodense)than that ofeosinophils purified from healthyindividuals(normodense)
(2, 3). As compared with normodense eosinophils, hypodense eosinophils exhibit
increases in calcium ionophore A23187-stimulated leukotriene C4 (LTC4) genera-
tion(4) and antibody-dependent helminthic cytotoxicity (3). The percentage ofcir-
culatinghypodense eosinophilsdirectly correlates with thedegree ofperipheral blood
eosinophilia (5), butthe factors that may regulate the eosinophil phenotype in IHES
have not been determined previously.
Acontinuous exposure ofnormodense eosinophilsto recombinant human granu-
locyte/macrophage colony-stimulating factor (rGM-CSF) (6), human rIL-3 (7),
purified murine IL-5 or human rIL-5 (8) allows them to be maintained ex vivo for
at least 2 wk. During this interval, the eosinophils become hypodense and exhibit
both augmented calcium ionophore-stimulated LTC4 generation and antibody-de-
pendent cytotoxicity against Schistosoma mansoni larvae. The similarity between
hypodense eosinophils, which are generated in vitroby the exposure ofnormodense
eosinophilsto specific cytokines, and hypodense eosinophils, which are freshly isolated
from theperipheral blood ofpatientswith IHES, prompted an analysisofeosinophil
phenotypes and cytokine activities in the peripheral blood of patients with IHES.
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Materials and Methods
BriefDefinitive Report
Patients.
￿
Three patients underwent diagnostic studies to rule out collagen-vascular dis-
eases, helminthic infections, neoplasia, drug reactions, atopy, or asthma, and each fulfilled
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the diagnostic criteria for IHES (1). Patient 1 was a 28-yr-old male with a 4-yr history of
eosinophilia and hepatosplenomegaly complicated by pulmonary infiltrates, hypoxemia, and
an acute peripheral myopathy. Patient 2 was a 29-yr-old male with a 3-yr history of eosinophilia
complicated by endomyocardial fibrosis and thrombosis resulting in mitral regurgitation. Pa-
tient 3 was a 62-yr-old male with a 6-yr history of eosinophilia complicated by interstitial
nephritis, cortical blindness, and seizures. None ofthese patients responded clinically to op-
timal doses ofcorticosteroids. Patient 1 was evaluated while receiving no therapy, or therapy
with hydroxyurea, corticosteroids, cyclosporin A, or combinations thereof. Patient 2 was evalu-
ated while being treated with leukoplasmapheresis and vincristine. Patient 3 underwent study
while receiving cyclophosphamide and corticosteroids.
Eosinophil Isolation.
￿
Eosinophils were isolated from the peripheral blood of 21 different
reference donors, who were healthy or were diagnosed with allergic rhinitis and/or asthma.
Eosinophils were purified from the peripheral blood of the three patients with IHES and
the reference donors by the centrifugation of individual dextran (BDH Chemicals, Poole,
England) sedimented erythrocyte/leukocyte preparations through discontinuous layers of
metrizamide (Nyegaard and Co., Oslo, Norway) of 18-24% (wt/vol) (6). Eosinophils recov-
ered from the 22/23 and 23/24% metrizamide interfaces and the cell pellet were designated
as normodense. Eosinophils recovered from the medium/18, 18/20, and 20/21 , 10 metrizamide
interfaces were designated as hypodense (6). Initial cell viability in all experiments was >98%
as assessed by Trypan blue (Gibco Laboratories, Grand Island, NY) exclusion.
Eosinophil Viability in Culture.
￿
Freshly isolated eosinophils (2-10 x 105 cells) were sus-
pended in 2 ml of enriched medium (RPMI 1640 supplemented with 100 U/ml of penicillin,
100,ug/ml ofstreptomycin, 10 jig/ml ofgentamicin, 2 MM L-glutamine, 0.1 mM nonessential
amino acids and 10% [vol/vol] FCS serum [Gibco Laboratories]), and were maintained in
35-mm plastic culture dishes at 37'C in a 5% C02 'atmosphere under various conditions
(6): enriched medium alone; enriched medium supplemented with 10 pM rGM-CSF (ex-
pressed in monkey COS cells and provided by Dr. J. Gasson, University of California at
Los Angeles, CA) in the presence of a monolayer of mouse 3T3 fibroblasts; and enriched
medium supplemented with 25% (vol/vol) serum from Patient 1 with IHES. Neutrophils
and mononuclear cells did not survive beyond 48 h of culture.
For experiments in 96-well, flat-bottomed microtiter plates, freshly isolated eosinophils
(5-10 x 104 cells) were suspended in 200-pl of enriched medium alone or medium sup-
plemented with 10 pM rGM-CSF, 10 pM rIL-3 (expressed in COS cells and generously
provided by Dr. Y.-C. Yang, Genetics Institute, Cambridge, MA), 1 pM IL-5 (purified from
the conditioned medium ofthe helper T cell line, D10.G4.1, and generously provided by Dr.
D. T. McKenzie, University ofCalifornia at San Diego, LaJolla, CA), 1 pM rIL-5 (expressed
in COS cells and provided by Dr. S. C . Clark, Genetics Institute), or defined concentrations
of human serum or plasma (7). For some experiments, various dilutions of heat-inactivated
(56°C for 30 min) neutralizing rabbit polyclonal antiserum against rGM-CSF (provided by
Dr. J. Gasson) or rIL-3 (provided by Dr. Y.-C. Yang), or a rat mAb against murine IL-5
(9) (provided as unpurified ascites fluid by Dr. K. Takatsu, Kumamoto University Medical
School, Honjo, Kumamoto, Japan) were preincubated for 150 min at 37°C with enriched
medium containing heat-inactivated FCS with or without added cytokine or human serum
or plasma. The effect of these treatments on cell viability was determined by Trypan blue
exclusion after 48-72 h of culture.
Eosinophil Functional Studies and Density Gradient Sedimentation.
￿
Freshly isolated eosinophils
were assessed for their ability to kill antibody-coated and uncoated S. mansoni larvae after
24 h (6). The calcium ionophore-stimulated generation of LTC4 by eosinophils before and
after 7 d of culture was assessed by stimulating eosinophils with 2 .5 pM A23187 (Calbiochem-
Behring Corp., San Diego, CA), and the methanolic extract was analyzed by RIA (10).
Results
Comparative Functional StudiesofFreshly Isolated Hypodense andNormodense Eosinophils.
Less than 3% of the eosinophils from the reference donors were hypodense. The
normodense eosinophil gradient fractions from the reference donors contained 90t 1% eosinophils and 10 ± 1% neutrophils (mean t SEM; n = 7). 61 t 23%
(n = 3; p < 0.05) of the eosinophils isolated from the three patients with IHES were
hypodense; these fractions (18/20 and 20/21% metrizamide) contained 78 t 6%
eosinophils, 17 ± 4% neutrophils, and 5 t 3% mononuclear cells. The normodense
eosinophil gradient fractions from the patients with IHES contained 98 t 1% eo-
sinophils and 2 t 1% neutrophils.
In the absence of immune sera, eosinophils from the reference donors killed <5%
of the larvae (n = 3), normodense eosinophils from the patients killed 8 ± 7% (n
= 2) of the larvae, and hypodense eosinophils from thepatients mediated astriking
helminthic cytotoxicity of 30 t 8% (n = 3; p < 0.05). With antisera, cytotoxicity
mediated by the eosinophils from the reference donors was increased to 14 t 2%
(n = 17), and normodense and hypodense eosinophil populations from the patients
with IHES increased their antibody-dependent helminthic cytoxicity to 40 t 10
and 50 ± 17%, respectively (n = 3; p < 0.001). In comparison to the 20 t 9 ng
of LTC4/106 cells generated by the calcium ionophore-stimulated normodense eosin-
ophils from the referencedonors (n = 15), both normodense and hypodenseeosino-
phil populations from the patients produced strikingly augmented quantities of
LTC4 of 69 ± 12 and 98 ± 9 ng/106 cells, respectively (n = 3; p < 0.001).
Comparative Ex Vivo Viability ofFreshly Isolated Normodense and Hypodense Eosinophil&.
Only 17 ± 8% of the initial number of eosinophils from the reference donors were
still viable after 48 h of culture. Greater survival was manifest by the normodense
eosinophils isolated from the patients with IHES (33 t 8% at 48 h). The percentage
of hypodense eosinophils from the patients that survived in culture after 48 h in
the absence of exogenous cytokines was 73 t 717o (Fig. 1). As assessed by light mi-
croscopy, no mitotic figures were observed in any population ofcultured eosinophils.
After 7 d, rGMCSFmediated survival in culture with 3T3 fibroblasts was 51 ±
7% (n = 3), 52 ± 20% (n = 2), and66 t 10% (n = 3) fornormodense eosinophils
from the reference donors, normodense eosinophils from the patients with IHES,
and hypodense eosinophils from the patients with IHES, respectively.
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FIGURE 1.
￿
Time course forthe survival offreshlyisolated
eosinophil populations. Hypodense (O) and normodense
(") eosinophils from the patients with IHES and nor-
modense (") eosinophils from the reference donors were
maintained inenriched medium alone. Data forhypodense
eosinophils from the patients with IHES (n = 3) andnor-
modenseeosinophils from thereferencedonors (n = 5) are
expressed as the mean t SEM. Data for normodense eo-
sinophilsfrom thepatients with IHES (n = 2) areexpressed
as themean andthe span oftherange. Inadequate numbers
of normodense eosinophils were obtained from Patient 2
forevaluaton. Statistical comparisons foreosinophil popu-
lationsfrom patients with IHES were made to normodense
eosinophils from the reference donors (`, p < 0.05).346
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FIGURE 2 .
￿
Influence of sera or plasma on eo-
sinophil viability ex vivo. Normodense eosinophils
from the referencedonors were cultured for 48-72 w h in enriched medium supplemented with in- , i
ao 1
￿
cremental concentrations ofindividual serum(Pa-
tients 1 and 3) or plasma (Patient 2) samples from
the patients with IHES (O) (n = 3), or serum
or plasma from the individual reference donors
(A) (n = 5) . Data are expressed as the mean t
20
￿
SEM . For eosinophils maintained in enriched
p
￿
medium supplemented with sera or plasma from
the IHES patients, statistical comparisons were
I
￿
made to replicate eosinophils maintained in
10 25 50 medium supplemented with sera or plasma from
SERUM OR PLASMA (%)
￿
the reference donors (`, p < 0.05) .
E]fect ofSerum and Plasmafrom Patients with1HES on the ViabilityofNormodenseEosinoßhils.
Whennormodense eosinophils from the reference donors were cultured for 48-72 h
in enriched medium supplemented with serum orplasma from individual patients
with IHES, a dose-dependent enhancement of eosinophil viability occurred (Fig .
2) . When dose-response curves for rGM-CSF and serum from Patient 1 were per-
formed in parallel on replicate normodense eosinophils (n = 4), 5 pM rGM-CSF
sustained eosinophil viability at the same level as 10% serum .
Normodense eosinophils from two different reference donors were cultured for
7 d in enriched medium supplemented with 25% serum from Patient 1 . Eosinophil
survival was 66 t 2%, and 77 t 1% of these cells were converted to hypodense
sedimenting cells. These cultured eosinophils generated 145 t 16 ng LTC4/106 cal-
cium ionophore-stimulated cells (n = 2), as compared with 35 t 1 ng from freshly
isolated normodense eosinophils from the same donors .
Antibody Neutralization ofthe Viability SustainingActivity in IHES Serum and Plasma.
￿
At
optimal dilutions of 1:250 (vol/vol) for anti-GM-CSF and anti-IL-3, and 1:100 for
anti-IL-5 as defined by inhibition of the appropriate cytokine, no crossreactivity
in neutralizing activities was noted. Anti-IL-5 neutralized the viability-sustaining
activity of 1 pM rIL-5 in a dose-dependent manner with complete neutralization
at dilutions 41 :1,000 . Preincubation of 25 or 10% sera from Patients 1 and 3 and
plasma from Patient 2with a 1 :100 dilution ofanti-IL-5 diminished mean eosinophil
viability after 72 h from 58 t 5 and 44 t 12% to 26 t 3 and20 t I%, respectively
(Fig . 3) . 1 :250 dilutions of anti-GM-CSF and anti-IL-3 did not attenuate the via-
bility ofnormodense eosinophils maintained 72 h in enriched medium supplemented
FIGURE 3 .
￿
Influence of neutralizing antibody against IL-5 on the
viability-sustaining activity ofIHES sera or plasma. Normodense eo-
sinophils from the reference donors were cultured for 48-72 h in en-
richedmedium alone, or medium supplemented with 10 or 25% serum
orplasmafrom the three individual IHES patients (stippledbars) . Repli-
cate serumor plasma sampleswere preincubated with 1 :100 dilutions
ofneutralizing antibody against IL-5 (crosshatched bars) . Data are ex-
pressed as the mean t SEM (n = 3) .BRIEF DEFINITIVE REPORT
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with 25 or 10% serum from Patients 1 and 3. Plasma from Patient 2 was not evalu-
ated with these antisera. The viability for replicate normodense eosinophils main-
tained in enriched medium alonewas 18 t 4% (n = 3). The addition of anti-IL-5 to
serum containing rGM-CSF during the preincubation period did not alter the in-
crease in viability after 72 h which was 60 t 3% as compared with 21 t 8% without
GM-CSF (n = 2). Replicate eosinophils maintained in medium alone, medium sup-
plementedwith 10 pM-rGM-CSF alone, or medium supplemented with 25 % serum
alone had a viability of 15 t 5%, 77 t 2%, and 64 t 14% (n = 2), respectively.
Discussion
The similar properties between the in vivo-derived hypodense sedimenting eo-
sinophils associated with a variety of eosinophilic disorders, and the hypodense eo-
sinophils generated in vitro by the exposure of normodense peripheral blood-de-
rived eosinophils to GM-CSF, IL-3, or IL-5, prompted a detailed analysis of the
eosinophil phenotypes and cytokine activities in the peripheral blood of three pa-
tients with corticosteroid-unresponsive IHES. 61% of the eosinophils from the pa-
tients with IHES were hypodense. Both hypodense andnormodense eosinophil popu-
lations from the IHES patients demonstrated an augmented capacity to generate
LTC4 upon calcium ionophore stimulation (5-fold and 3.5-fold, respectively) and
an enhanced capacity to mediate antibody-dependent cytotoxicity againstS. mansoni
larvae (3 .5-fold and 3-fold, respectively), as compared with eosinophils from the ref-
erence donors. Hypodense eosinophils from the patients were able to mediate
significant cytotoxicity against the larvae even in the absence of antibody sensitiza-
tion. Theability to kill unopsonizedS. mansoni larvae may be relevant to the finding
ofeosinophil degranulationin varioustissues of patients with IHES (11). Thehypodense
eosinophils exhibited a t1/2 for ex vivo viability of 3.5 d, whereas <10% of the nor-
modense eosinophils from either the reference donors or the patients survived an
equivalent duration. Thesein vitro findings may be relevant to in vivo circumstances,
since a previous study which made no distinction for eosinophil density indicated
that autologous chromium-labeled peripheral blood eosinophils from patients with
1HES may have a prolonged life span in vivo (12) .
Serum or plasma from the patients with IHES contained an activity that in a
dose-dependent manner was capable of conferring extended viability, augmented
function, and the property of hypodensity to normodense eosinophils from the ref-
erence donors. An ED5o of 8% serum or plasma was extrapolated for the main-
tenance ofeosinophil viability ex vivo, and this concentration was equivalent in ac-
tivity to N5 pM GM-CSF. No similaractivity was detected in the serum and plasma
of the reference donors. A monospecific neutralizing antibody against IL-5 com-
pletelyabolishedthis activity,but antiseraagainstGM-CSF or IL-3 were without effect.
The finding of abnormal quantities of immunoreactive IL-5 in the blood of pa-
tients with IHES could account for several clinical aspects of this disorder. IL-5 is
unique amongthe hematopoietins in its abilityto cause granulocytosis with a selec-
tive eosinophilia in vitro and in vivo (13). These altered eosinophil phenotypes with
a putative pathobiologic action in patients with IHES may arise as a consequence
of abnormal quantities of IL-5 in the peripheral blood.348
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Summary
We report that the hypodense eosinophil population in three patients with
corticosteroid-unresponsive IHES was uniquely long lived ex vivo in the absence
of exogenous cytokines . Serum or plasma from these patients conferred prolonged
viability ex vivo to normodense eosinophils from reference donors and converted
them to a functionally activated hypodense phenotype . In that antibody against IL-
5 neutralized this activity in IHES serum, excessive quantities ofthis cytokine may
account for the characteristic eosinophilia and long-lived, functionally augmented
eosinophil phenotype in this disorder.
Receivedfor publication 27 February 1989 and in revisedform 27 March 1989 .
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